Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis
Antisclerostin monoclonal antibodies have shown their ability to increase bone density in phase II and III trials of men and women with osteoporosis but could potentially have the opposite effect in...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Arthritis | Endocrinology | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology | Women